3beta-hydroxy-17-(1h-benzimidazole-1-yl)androsta-5,16-diene profile

3-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene: has antineoplastic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	11188409
CHEMBL ID	2105738
CHEBI ID	177536
SCHEMBL ID	939234
MeSH ID	M0484956

Synonym
HY-70006
(3s,8r,9s,10r,13s,14s)-17-(benzimidazol-1-yl)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1h-cyclopenta[a]phenanthren-3-ol
851983-85-2
CHEBI:177536
3-hydroxy-17-(1h-benzimidazole-1-yl)androsta-5,16-diene
vn-124-1
galeterone
17-(1h-benzimidazol-1-yl)androsta-5,16-dien-3beta-ol
AKOS005146524
D10125
galeterone (usan)
vn/124-1
tok 001
vn/124
unii-wa33e149sw
galeterone [usan:inn]
androsta-5,16-dien-3-ol, 17-(1h-benzimidazol-1-yl)-, (3beta)-
tok-001 ,
3beta-hydroxy-17-(1h-benzimidazole-1-yl)androsta-5,16-diene
wa33e149sw ,
CHEMBL2105738
vn-124
vn 124
BCPP000040
bdbm50435990
CS-0334
androsta-5,16-dien-3-ol, 17-(1h-benzimidazol-1-yl)-, (3.beta.)-
galeterone [who-dd]
galeterone [usan]
galeterone [inn]
(3beta)-17-(1h-benzimidazol-1-yl)androsta-5,16-dien-3-ol
J-501178
SCHEMBL939234
3beta-hydroxy-17-(1h-benzimidazol-1-yl)-androsta-5,16-diene
PAFKTGFSEFKSQG-PAASFTFBSA-N
3beta-hydroxy-17-(1h-benzimidazol-1-yl)androsta-5,16-diene
gtpl8638
galaterone
AC-26549
(3?)-17-(1h-benzimidazol-1-yl)androsta-5,16-dien-3-ol
EX-A1025
tok-001; galeterone
(3s,8r,9s,10r,13s,14s)-17-(1h-benzo[d]imidazol-1-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol
galeterone, >=98% (hplc)
mfcd16660907
tok-001 (galeterone)
tok-001(galeterone)
DB12415
Q5518498
vn/124-1;tok-001;vn 124;tok001;tok 001
BCP02827
tok-001;vn-124-1
AMY27882
AS-56204
DTXSID101025602

Excerpt	Reference	Relevance
" In our desire to optimize the potency of 5, compounds 6 (3ξ-fluoro-) and 9 (3β-sulfamate-) designed to increase the stability and oral bioavailability of 5, respectively were evaluated in vivo."	( Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model. Ates-Alagoz, Z; Brodie, AM; Bruno, RD; Gediya, LK; Godbole, AM; Njar, VC; Purushottamachar, P; Vasaitis, TS, 2011)	0.37
" Despite this increase, the bioavailability of this formulation may have been insufficient and contributed to its clinical failure."	( Can the Oral Bioavailability of the Discontinued Prostate Cancer Drug Galeterone Be Improved by Processing Method? KinetiSol® Outperforms Spray Drying in a Head-to-head Comparison. Davis, DA; Gala, U; Kucera, S; Miller, D; Thompson, SA; Williams, RO, 2023)	0.91

Excerpt	Relevance	Reference
" In dose-response F2H experiments, we compared the potencies of abiraterone, bicalutamide, enzalutamide, flutamide, and galeterone/TOK-001 to prevent the dihydrotestosterone-induced N/C interaction in wt AR."	( The fluorescent two-hybrid assay for live-cell profiling of androgen receptor modulators. Bogner, J; Hickson, I; Romer, T; Yurlova, L; Zolghadr, K, 2017)	0.46

Role	Description
androgen	A sex hormone that stimulates or controls the development and maintenance of masculine characteristics in vertebrates by binding to androgen receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
3-hydroxy steroid	Any hydroxy steroid carrying a hydroxy group at position 3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Steroid 17-alpha-hydroxylase/17,20 lyase	Homo sapiens (human)	IC50 (µMol)	0.2530	0.0020	0.9818	4.7300	AID1199394; AID1375969; AID1410947; AID1636760; AID1864638; AID754122
Steroid 21-hydroxylase	Homo sapiens (human)	IC50 (µMol)	0.1626	0.0007	2.3543	9.0100	AID1375970; AID1410948
Androgen receptor	Homo sapiens (human)	IC50 (µMol)	1.1080	0.0000	0.8753	10.0000	AID1864639
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Androgen receptor	Homo sapiens (human)	EC50 (µMol)	0.6400	0.0000	0.2079	4.3000	AID1199395; AID1199396; AID754108
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
steroid biosynthetic process	Steroid 17-alpha-hydroxylase/17,20 lyase	Homo sapiens (human)
androgen biosynthetic process	Steroid 17-alpha-hydroxylase/17,20 lyase	Homo sapiens (human)
glucocorticoid biosynthetic process	Steroid 17-alpha-hydroxylase/17,20 lyase	Homo sapiens (human)
sex differentiation	Steroid 17-alpha-hydroxylase/17,20 lyase	Homo sapiens (human)
steroid metabolic process	Steroid 17-alpha-hydroxylase/17,20 lyase	Homo sapiens (human)
hormone biosynthetic process	Steroid 17-alpha-hydroxylase/17,20 lyase	Homo sapiens (human)
progesterone metabolic process	Steroid 17-alpha-hydroxylase/17,20 lyase	Homo sapiens (human)
steroid biosynthetic process	Steroid 21-hydroxylase	Homo sapiens (human)
glucocorticoid biosynthetic process	Steroid 21-hydroxylase	Homo sapiens (human)
mineralocorticoid biosynthetic process	Steroid 21-hydroxylase	Homo sapiens (human)
steroid metabolic process	Steroid 21-hydroxylase	Homo sapiens (human)
sterol metabolic process	Steroid 21-hydroxylase	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Androgen receptor	Homo sapiens (human)
MAPK cascade	Androgen receptor	Homo sapiens (human)
in utero embryonic development	Androgen receptor	Homo sapiens (human)
regulation of systemic arterial blood pressure	Androgen receptor	Homo sapiens (human)
epithelial cell morphogenesis	Androgen receptor	Homo sapiens (human)
transcription by RNA polymerase II	Androgen receptor	Homo sapiens (human)
signal transduction	Androgen receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Androgen receptor	Homo sapiens (human)
cell-cell signaling	Androgen receptor	Homo sapiens (human)
spermatogenesis	Androgen receptor	Homo sapiens (human)
single fertilization	Androgen receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Androgen receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Androgen receptor	Homo sapiens (human)
positive regulation of gene expression	Androgen receptor	Homo sapiens (human)
male somatic sex determination	Androgen receptor	Homo sapiens (human)
intracellular estrogen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
androgen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
intracellular receptor signaling pathway	Androgen receptor	Homo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
Leydig cell differentiation	Androgen receptor	Homo sapiens (human)
multicellular organism growth	Androgen receptor	Homo sapiens (human)
positive regulation of phosphorylation	Androgen receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Androgen receptor	Homo sapiens (human)
positive regulation of insulin-like growth factor receptor signaling pathway	Androgen receptor	Homo sapiens (human)
positive regulation of cell differentiation	Androgen receptor	Homo sapiens (human)
negative regulation of integrin biosynthetic process	Androgen receptor	Homo sapiens (human)
positive regulation of integrin biosynthetic process	Androgen receptor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Androgen receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Androgen receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase III	Androgen receptor	Homo sapiens (human)
insulin-like growth factor receptor signaling pathway	Androgen receptor	Homo sapiens (human)
regulation of developmental growth	Androgen receptor	Homo sapiens (human)
animal organ formation	Androgen receptor	Homo sapiens (human)
male genitalia morphogenesis	Androgen receptor	Homo sapiens (human)
epithelial cell proliferation	Androgen receptor	Homo sapiens (human)
negative regulation of epithelial cell proliferation	Androgen receptor	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Androgen receptor	Homo sapiens (human)
activation of prostate induction by androgen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
morphogenesis of an epithelial fold	Androgen receptor	Homo sapiens (human)
lateral sprouting involved in mammary gland duct morphogenesis	Androgen receptor	Homo sapiens (human)
prostate gland growth	Androgen receptor	Homo sapiens (human)
prostate gland epithelium morphogenesis	Androgen receptor	Homo sapiens (human)
epithelial cell differentiation involved in prostate gland development	Androgen receptor	Homo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesis	Androgen receptor	Homo sapiens (human)
mammary gland alveolus development	Androgen receptor	Homo sapiens (human)
positive regulation of epithelial cell proliferation involved in prostate gland development	Androgen receptor	Homo sapiens (human)
cellular response to steroid hormone stimulus	Androgen receptor	Homo sapiens (human)
cellular response to estrogen stimulus	Androgen receptor	Homo sapiens (human)
cellular response to testosterone stimulus	Androgen receptor	Homo sapiens (human)
seminiferous tubule development	Androgen receptor	Homo sapiens (human)
non-membrane-bounded organelle assembly	Androgen receptor	Homo sapiens (human)
positive regulation of miRNA transcription	Androgen receptor	Homo sapiens (human)
regulation of protein localization to plasma membrane	Androgen receptor	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway	Androgen receptor	Homo sapiens (human)
male gonad development	Androgen receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Androgen receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
steroid 17-alpha-monooxygenase activity	Steroid 17-alpha-hydroxylase/17,20 lyase	Homo sapiens (human)
iron ion binding	Steroid 17-alpha-hydroxylase/17,20 lyase	Homo sapiens (human)
oxygen binding	Steroid 17-alpha-hydroxylase/17,20 lyase	Homo sapiens (human)
heme binding	Steroid 17-alpha-hydroxylase/17,20 lyase	Homo sapiens (human)
17-alpha-hydroxyprogesterone aldolase activity	Steroid 17-alpha-hydroxylase/17,20 lyase	Homo sapiens (human)
steroid 21-monooxygenase activity	Steroid 21-hydroxylase	Homo sapiens (human)
steroid binding	Steroid 21-hydroxylase	Homo sapiens (human)
iron ion binding	Steroid 21-hydroxylase	Homo sapiens (human)
steroid hydroxylase activity	Steroid 21-hydroxylase	Homo sapiens (human)
heme binding	Steroid 21-hydroxylase	Homo sapiens (human)
17-hydroxyprogesterone 21-hydroxylase activity	Steroid 21-hydroxylase	Homo sapiens (human)
progesterone 21-hydroxylase activity	Steroid 21-hydroxylase	Homo sapiens (human)
transcription cis-regulatory region binding	Androgen receptor	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Androgen receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Androgen receptor	Homo sapiens (human)
RNA polymerase II general transcription initiation factor binding	Androgen receptor	Homo sapiens (human)
transcription coactivator binding	Androgen receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Androgen receptor	Homo sapiens (human)
chromatin binding	Androgen receptor	Homo sapiens (human)
DNA-binding transcription factor activity	Androgen receptor	Homo sapiens (human)
nuclear receptor activity	Androgen receptor	Homo sapiens (human)
G protein-coupled receptor activity	Androgen receptor	Homo sapiens (human)
signaling receptor binding	Androgen receptor	Homo sapiens (human)
steroid binding	Androgen receptor	Homo sapiens (human)
androgen binding	Androgen receptor	Homo sapiens (human)
protein binding	Androgen receptor	Homo sapiens (human)
beta-catenin binding	Androgen receptor	Homo sapiens (human)
zinc ion binding	Androgen receptor	Homo sapiens (human)
enzyme binding	Androgen receptor	Homo sapiens (human)
ATPase binding	Androgen receptor	Homo sapiens (human)
molecular adaptor activity	Androgen receptor	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Androgen receptor	Homo sapiens (human)
POU domain binding	Androgen receptor	Homo sapiens (human)
molecular condensate scaffold activity	Androgen receptor	Homo sapiens (human)
estrogen response element binding	Androgen receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
endoplasmic reticulum	Steroid 17-alpha-hydroxylase/17,20 lyase	Homo sapiens (human)
endoplasmic reticulum membrane	Steroid 17-alpha-hydroxylase/17,20 lyase	Homo sapiens (human)
axon	Steroid 17-alpha-hydroxylase/17,20 lyase	Homo sapiens (human)
neuronal cell body	Steroid 17-alpha-hydroxylase/17,20 lyase	Homo sapiens (human)
endoplasmic reticulum membrane	Steroid 21-hydroxylase	Homo sapiens (human)
plasma membrane	Androgen receptor	Homo sapiens (human)
nucleus	Androgen receptor	Homo sapiens (human)
nucleoplasm	Androgen receptor	Homo sapiens (human)
cytoplasm	Androgen receptor	Homo sapiens (human)
cytosol	Androgen receptor	Homo sapiens (human)
nuclear speck	Androgen receptor	Homo sapiens (human)
chromatin	Androgen receptor	Homo sapiens (human)
protein-containing complex	Androgen receptor	Homo sapiens (human)
nucleus	Androgen receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (79)

Assay ID	Title	Year	Journal	Article
AID1347947	Antiproliferative activity against human HBL100 cells after 48 hrs by SRB assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Synthesis of unprecedented steroidal spiro heterocycles as potential antiproliferative drugs.
AID754122	Inhibition of human truncated CYP17A1 expressed in Escherichia coli	2013	Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12	Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
AID1864640	Induction of AR degradation in human LNCap cells incubated for 24 hrs by sandwich ELISA analysis	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.
AID1199400	Drug elimination constant in SCID mouse at 50 mg/kg, sc	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
AID1199402	Tmax in SCID mouse at 50 mg/kg, sc	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
AID1566984	Antiproliferative activity against AR-negative human PC3 cells assessed as cell viability at 10 uM measured after 72 hrs by resazurin dye based fluorescence assay relative to control	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Tetrahydropyrazolo[1,5-a]pyridine-fused steroids and their in vitro biological evaluation in prostate cancer.
AID1347952	Cytotoxicity against human hTERT-BJ cells assessed as cell growth inhibition after 48 hrs SRB assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Synthesis of unprecedented steroidal spiro heterocycles as potential antiproliferative drugs.
AID1566985	Antiproliferative activity against AR-positive human 22Rv1 cells harboring ARE14 construct assessed as cell viability at 10 uM measured after 72 hrs by resazurin dye based fluorescence assay relative to control	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Tetrahydropyrazolo[1,5-a]pyridine-fused steroids and their in vitro biological evaluation in prostate cancer.
AID1199403	Cmax in SCID mouse at 50 mg/kg, sc	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
AID1199417	Antitumor activity against human LAPC4 cells xenografted in SCID mouse assessed as tumor volume at 0.13 mmol/kg, sc dosed twice daily (Rvb = 2410.28 mm3)	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
AID754121	Induction of apoptosis in human CWR22Rv1 cells assessed as induction of PARP cleavage	2013	Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12	Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
AID1566986	Antiproliferative activity against AR-positive human VCaP cells assessed as cell viability at 10 uM measured after 72 hrs by resazurin dye based fluorescence assay relative to control	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Tetrahydropyrazolo[1,5-a]pyridine-fused steroids and their in vitro biological evaluation in prostate cancer.
AID1199395	Displacement of [3H]R1881 from androgen receptor in human LNCAP cells	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
AID1556813	Inhibition of R1881 induced-AR transcriptional activity in AR-positive human 22Rv1 cells harboring ARE14 construct at 10 uM after 24 hrs by luciferase assay relative to control	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines.
AID1199396	Displacement of [3H]R1881 from androgen receptor in human PC3 cells	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
AID1199416	Antitumor activity against human LAPC4 cells xenografted in SCID mouse assessed as reduction in tumor volume at 0.15 mmol/kg, sc dosed twice daily starting 1 day after tumor cell inoculation and measured after 16 weeks of treatment	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
AID1199401	AUC in SCID mouse at 50 mg/kg, sc	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
AID1566994	Inhibition of R1881 induced-AR transcriptional activity in AR-positive human 22Rv1 cells harboring ARE14 construct assessed as suppression of PSA expression after 24 hrs by immunoblot analysis	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Tetrahydropyrazolo[1,5-a]pyridine-fused steroids and their in vitro biological evaluation in prostate cancer.
AID1199407	Drug elimination constant in SCID mouse at 100 mg/kg, sc	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
AID1556806	Antiproliferative activity against AR-positive human C4-2 cells assessed as growth inhibition after 72 hrs by resazurin dye based fluorescence assay	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines.
AID1636754	Antitumor activity against human CWR22Rv1 cells xenografted in SCID mouse assessed as tumor growth inhibition at 0.15 mmol/kg, ip bid administered for 5 days per week relative to control	2016	ACS medicinal chemistry letters, Jul-14, Volume: 7, Issue:7	Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate.
AID754119	Inhibition of AR in human LNCaP cells at 15 uM after 24 hrs by luciferase reporter gene assay	2013	Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12	Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
AID1567000	Induction of apoptosis in AR-positive human VCaP cells assessed as cleaved PARP level at 5 to 20 uM after 24 hrs by immunoblot analysis	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Tetrahydropyrazolo[1,5-a]pyridine-fused steroids and their in vitro biological evaluation in prostate cancer.
AID1566989	Inhibition of AR transcriptional activity in AR-positive human 22Rv1 cells harboring ARE14 construct assessed as suppression of PSA expression at 10 uM after 24 hrs by immunoblot analysis	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Tetrahydropyrazolo[1,5-a]pyridine-fused steroids and their in vitro biological evaluation in prostate cancer.
AID1375970	Inhibition of C-terminal His-tagged recombinant human CYP21A2deltaH mutant expressed in Escherichia coli DH5alpha assessed as decrease in progesterone hydroxylation preincubated for 3 mins followed by NADPH addition measured after 10 mins in presence of c	2018	Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11	Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2.
AID754120	Induction of apoptosis in human LNCAP cells assessed as induction of PARP cleavage	2013	Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12	Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
AID1864636	Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability measured after 6 days by CellTiter-Glo assay	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.
AID1556828	Antiproliferative activity against AR-positive human C4-2 cells assessed as cell viability at 40 uM after 72 hrs by resazurin dye based fluorescence assay	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines.
AID1567006	Inhibition of R1881 induced-AR transcriptional activity in AR-positive human 22Rv1 cells harboring ARE14 construct at 10 uM after 24 hrs by luciferase assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Tetrahydropyrazolo[1,5-a]pyridine-fused steroids and their in vitro biological evaluation in prostate cancer.
AID1199414	Drug metabolism in mouse plasma assessed as retention time of metabolite by reverse phase HPLC method	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
AID1636762	Antiproliferative activity against human CWR22Rv1 cells after 7 days by MTT assay	2016	ACS medicinal chemistry letters, Jul-14, Volume: 7, Issue:7	Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate.
AID1347948	Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Synthesis of unprecedented steroidal spiro heterocycles as potential antiproliferative drugs.
AID1199419	Antitumor activity against human LAPC4 cells xenografted in SCID mouse with castration assessed as regression of tumor volume at 0.13 mmol/kg, sc dosed twice daily	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
AID1347946	Antiproliferative activity against human A549 cells after 48 hrs by SRB assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Synthesis of unprecedented steroidal spiro heterocycles as potential antiproliferative drugs.
AID754123	Cytotoxicity against human LNCAP cells after 7 days by MTT assay	2013	Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12	Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
AID1199399	Elimination half life in SCID mouse at 50 mg/kg, sc	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
AID1199411	Mean residence time in SCID mouse at 100 mg/kg, sc	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
AID1566983	Antiproliferative activity against AR-positive human LAPC4 cells assessed as cell viability at 10 uM measured after 72 hrs by resazurin dye based fluorescence assay relative to control	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Tetrahydropyrazolo[1,5-a]pyridine-fused steroids and their in vitro biological evaluation in prostate cancer.
AID1375969	Inhibition of C-terminal His-tagged recombinant human CYP17A1delta19H mutant expressed in Escherichia coli DH5alpha assessed as decrease in progesterone hydroxylation preincubated for 3 mins followed by NADPH addition measured after 10 mins in presence of	2018	Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11	Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2.
AID1636761	Antiproliferative activity against human LNCAP cells after 7 days by MTT assay	2016	ACS medicinal chemistry letters, Jul-14, Volume: 7, Issue:7	Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate.
AID1347950	Antiproliferative activity against human T47D cells after 48 hrs by SRB assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Synthesis of unprecedented steroidal spiro heterocycles as potential antiproliferative drugs.
AID754116	Down regulation of truncated AR-3 expression in human CWR22Rv1 by Western blotting analysis	2013	Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12	Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
AID1199405	Volume of distribution in SCID mouse at 50 mg/kg, sc	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
AID1556807	Antiproliferative activity against AR-positive human VCaP cells assessed as growth inhibition after 72 hrs by resazurin dye based fluorescence assay	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines.
AID1864638	Inhibition of human recombinant CYP17A1 incubated for 5 mins in presence of NADPH by LC-MS/MS analysis	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.
AID1864639	Antagonist activity at DHT-induced Androgen receptor transcriptional activity in human HEK293 cells measured after 24 hrs by Steady-Glo reagent based assay	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.
AID1347949	Antiproliferative activity against human SW1573 cells after 48 hrs by SRB assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Synthesis of unprecedented steroidal spiro heterocycles as potential antiproliferative drugs.
AID1199394	Inhibition of human CYP17 expressed in Escherichia coli	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
AID1375971	Selectivity ratio of IC50 for C-terminal His-tagged recombinant human CYP21A2deltaH mutant to IC50 for C-terminal His-tagged recombinant human CYP17A1delta19H mutant	2018	Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11	Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2.
AID1199415	Clearance in SCID mouse at 50 mg/kg, sc	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
AID1199409	Tmax in SCID mouse at 100 mg/kg, sc	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
AID1636760	Inhibition of CYP17 (unknown origin)	2016	ACS medicinal chemistry letters, Jul-14, Volume: 7, Issue:7	Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate.
AID1199404	Mean residence time in SCID mouse at 50 mg/kg, sc	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
AID754115	Down regulation of AR protein expression in human LNCAP cells at 5 uM after 48 hrs by DAPI staining-based immunocytochemical analysis	2013	Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12	Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
AID1566988	Inhibition of AR transcriptional activity in AR-positive human 22Rv1 cells harboring ARE14 construct assessed as suppression of NKX3.1 expression at 10 uM after 24 hrs by immunoblot analysis	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Tetrahydropyrazolo[1,5-a]pyridine-fused steroids and their in vitro biological evaluation in prostate cancer.
AID754118	Induction of AR-mediated growth inhibtion of human LNCAP cells at 15 uM after 24 hrs	2013	Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12	Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
AID1556829	Antiproliferative activity against AR-positive human VCaP cells assessed as cell viability at 40 uM after 72 hrs by resazurin dye based fluorescence assay	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines.
AID1199410	Cmax in SCID mouse at 100 mg/kg, sc	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
AID1556808	Antiproliferative activity against AR-negative human PC3 cells assessed as growth inhibition after 72 hrs by resazurin dye based fluorescence assay	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines.
AID1199397	Growth inhibition of human castration-resistant prostate cancer cells	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
AID1556805	Antiproliferative activity against AR-positive human 22Rv1 cells harboring ARE14 construct assessed as growth inhibition after 72 hrs by resazurin dye based fluorescence assay	2019	European journal of medicinal chemistry, Oct-01, Volume: 179	Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines.
AID1566993	Inhibition of R1881 induced-AR transcriptional activity in AR-positive human 22Rv1 cells harboring ARE14 construct assessed as suppression of NKX3.1 expression after 24 hrs by immunoblot analysis	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Tetrahydropyrazolo[1,5-a]pyridine-fused steroids and their in vitro biological evaluation in prostate cancer.
AID1550921	Inhibition of C-myc/DDK tagged human CYP17A1 expressed in HEK293T cells assessed as reduction in formation of 17-OHP at 10 uM incubated for 30 mins by LC-MS/MS analysis	2019	European journal of medicinal chemistry, Jun-01, Volume: 171	Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
AID1566982	Antiproliferative activity against AR-positive human LNCAP cells assessed as cell viability at 10 uM measured after 72 hrs by resazurin dye based fluorescence assay relative to control	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Tetrahydropyrazolo[1,5-a]pyridine-fused steroids and their in vitro biological evaluation in prostate cancer.
AID754107	Inhibition of DHT-mediated AR transactivation in human LNCaP cells at 10 uM after 18 hrs by luciferase reporter gene assay relative to control	2013	Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12	Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
AID1199412	Volume of distribution in SCID mouse at 100 mg/kg, sc	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
AID1636757	Induction of androgen receptor degradation in human LNCAP cells at 15 uM after 24 hrs by Western blot analysis	2016	ACS medicinal chemistry letters, Jul-14, Volume: 7, Issue:7	Identification of Novel Steroidal Androgen Receptor Degrading Agents Inspired by Galeterone 3β-Imidazole Carbamate.
AID1566995	Induction of apoptosis in R1881-activated AR-positive human 22Rv1 cells harboring ARE14 construct assessed as cleaved PARP level at 5 to 20 uM after 24 hrs by immunoblot analysis	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Tetrahydropyrazolo[1,5-a]pyridine-fused steroids and their in vitro biological evaluation in prostate cancer.
AID1199406	Elimination half life in SCID mouse at 100 mg/kg, sc	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
AID754108	Displacement of [3H]R1881 from AR in human LNCaP cells after 2 hrs by scintillation counting analysis	2013	Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12	Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
AID1199418	Antitumor activity against human LAPC4 cells xenografted in SCID mouse assessed as regression of tumor volume at 0.13 mmol/kg, sc dosed twice daily	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
AID1199413	Retention time in mouse plasma by reverse phase HPLC method	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
AID754117	Down regulation of full length AR expression in human CWR22Rv1 by Western blotting analysis	2013	Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12	Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
AID1199408	AUC in SCID mouse at 100 mg/kg, sc	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
AID1347951	Antiproliferative activity against human WiDr cells after 48 hrs by SRB assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Synthesis of unprecedented steroidal spiro heterocycles as potential antiproliferative drugs.
AID754113	Down regulation of AR protein expression in human LNCAP cells at 15 uM after 24 hrs by Western blotting analysis	2013	Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12	Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
AID1864637	Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability at 10 uM measured after 6 days by CellTiterGlo assay relative to control	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.
AID1345290	Human CYP17A1 (CYP11, CYP17, CYP19, CYP20 and CYP21 families)	2005	Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8	Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
AID1346888	Human Androgen receptor (3C. 3-Ketosteroid receptors)	2005	Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8	Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (8.16)	29.6817
2010's	35 (71.43)	24.3611
2020's	10 (20.41)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	2 (4.00%)	5.53%
Reviews	8 (16.00%)	6.00%
Case Studies	2 (4.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	38 (76.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
bicalutamide bicalutamide: approved for treatment of advanced prostate cancer. N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide : A member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group.. bicalutamide : A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.	3.17	5	0	(trifluoromethyl)benzenes; monocarboxylic acid amide; monofluorobenzenes; nitrile; sulfone; tertiary alcohol
flutamide Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.	2.47	2	0	(trifluoromethyl)benzenes; monocarboxylic acid amide	androgen antagonist; antineoplastic agent
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	3.86	3	0	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
niclosamide Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48). niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.	3.35	1	0	benzamides; C-nitro compound; monochlorobenzenes; salicylanilides; secondary carboxamide	anthelminthic drug; anticoronaviral agent; antiparasitic agent; apoptosis inducer; molluscicide; piscicide; STAT3 inhibitor
prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.	3.23	1	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
dehydroepiandrosterone Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.. dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.	2.66	2	0	17-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; androstanoid	androgen; human metabolite; mouse metabolite
androstenedione Androstenedione: A delta-4 C19 steroid that is produced not only in the TESTIS, but also in the OVARY and the ADRENAL CORTEX. Depending on the tissue type, androstenedione can serve as a precursor to TESTOSTERONE as well as ESTRONE and ESTRADIOL.. androst-4-ene-3,17-dione : A 3-oxo Delta(4)-steroid that is androst-4-ene substituted by oxo groups at positions 3 and 17. It is a steroid hormone synthesized in the adrenal glands and gonads.	2.15	1	0	17-oxo steroid; 3-oxo-Delta(4) steroid; androstanoid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite
norethindrone Norethindrone: A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for CONTRACEPTION.. norethisterone : A 17beta-hydroxy steroid that is testosterone in which the hydrogen at position 17 is replaced by an ethynyl group and in which the methyl group attached to position 10 is replaced by hydrogen.	2.06	1	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound; tertiary alcohol	progestin; synthetic oral contraceptive
glyoxal [no description available]	2.41	1	0	dialdehyde	agrochemical; allergen; pesticide; plant growth regulator
pregnenolone [no description available]	2.15	1	0	20-oxo steroid; 3beta-hydroxy-Delta(5)-steroid; C21-steroid	human metabolite; mouse metabolite
benzoxazoles 1,3-benzoxazole : A benzoxazole in which the benzene ring is fused to a 1,3-oxazole ring across positions 4 and 5.. benzoxazole : Compounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton.	2.25	1	0	1,3-benzoxazoles; mancude organic heterobicyclic parent
isoxazoles Isoxazoles: Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.. isoxazole : A monocyclic heteroarene with a structure consisting of a 5-membered ring containing three carbon atoms and an oxygen and nitrogen atom adjacent to each other. It is the parent of the class of isoxazoles.. isoxazoles : Oxazoles in which the N and O atoms are adjacent.	3.35	1	0	isoxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
oxazoles Oxazoles: Five-membered heterocyclic ring structures containing an oxygen in the 1-position and a nitrogen in the 3-position, in distinction from ISOXAZOLES where they are at the 1,2 positions.. 1,3-oxazole : A five-membered monocyclic heteroarene that is an analogue of cyclopentadiene with O in place of CH2 at position 1 and N in place of CH at position 3.. oxazole : An azole based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom.	2.25	1	0	1,3-oxazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
pyrazines Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.	2.02	1	0	diazine; pyrazines	Daphnia magna metabolite
dihydrotestosterone Dihydrotestosterone: A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.. 17beta-hydroxyandrostan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4-5 double bond has been reduced to a single bond with unspecified configuration at position 5.. 17beta-hydroxy-5alpha-androstan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4,5 double bond has been reduced to a single bond with alpha-configuration at position 5.	2.15	1	0	17beta-hydroxy steroid; 17beta-hydroxyandrostan-3-one; 3-oxo-5alpha-steroid	androgen; Daphnia magna metabolite; human metabolite; mouse metabolite
formestane [no description available]	2.15	1	0	17-oxo steroid; 3-oxo-Delta(4) steroid; enol; hydroxy steroid	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
finasteride Finasteride: An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.. finasteride : An aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia.	2.02	1	0	3-oxo steroid; aza-steroid; delta-lactam	androgen antagonist; antihyperplasia drug; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	4.14	2	0	1,2,3-triazole
abiraterone [no description available]	6.47	21	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; pyridines	antineoplastic agent; EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	2.6	1	0	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
17-(3-pyridyl)androsta-5,16-dien-3-one 17-(3-pyridyl)androsta-5,16-dien-3-one: a steroidal inhibitor of cytochrome P450(17alpha)/C17-20 lyase; structure given in first source	2.17	1	0
metribolone Metribolone: A synthetic non-aromatizable androgen and anabolic steroid. It binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.. 17beta-hydroxy-17-methylestra-4,9,11-trien-3-one : A synthetic non-aromatisable androgen and anabolic steroid. It binds strongly to the androgen receptor and has therefore also been used as an affinity label for this receptor in the prostate and in prostatic tumors.	2.21	1	0	17beta-hydroxy steroid; 3-oxo steroid; anabolic androgenic steroid	androgen
thapsigargin Thapsigargin: A sesquiterpene lactone found in roots of THAPSIA. It inhibits SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES.. thapsigargin : An organic heterotricyclic compound that is a hexa-oxygenated 6,7-guaianolide isolated fron the roots of Thapsia garganica L., Apiaceae. A potent skin irritant, it is used in traditional medicine as a counter-irritant. Thapsigargin inhibits Ca(2+)-transporting ATPase mediated uptake of calcium ions into sarcoplasmic reticulum and is used in experimentation examining the impacts of increasing cytosolic calcium concentrations.	2.04	1	0	butyrate ester; organic heterotricyclic compound; sesquiterpene lactone	calcium channel blocker; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
thiohydantoins Thiohydantoins: Sulfur analogs of hydantoins with one or both carbonyl groups replaced by thiocarbonyl groups.	5.2	4	0
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	2.05	1	0	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
everolimus [no description available]	2.05	1	0	cyclic acetal; cyclic ketone; ether; macrolide lactam; primary alcohol; secondary alcohol	anticoronaviral agent; antineoplastic agent; geroprotector; immunosuppressive agent; mTOR inhibitor
tanespimycin CP 127374: analog of herbimycin A	3.35	1	0	1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound; secondary amino compound	antineoplastic agent; apoptosis inducer; Hsp90 inhibitor
orteronel orteronel: non-steroidal 17,20-lyase inhibitor; structure in first source	4.96	4	0
abiraterone acetate Abiraterone Acetate: An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.. abiraterone acetate : A sterol ester obtained by formal condensation of the 3-hydroxy group of abiraterone with the carboxy group of acetic acid. A prodrug that is converted in vivo into abiraterone. Used for treatment of metastatic castrate-resistant prostate cancer.	3.19	1	0	pyridines; sterol ester	antineoplastic agent; EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor; prodrug
at 13387 (2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone: structure in first source. onalespib : A member of the class of isoindoles that is isoindole in which the amino group has been acylated by a 2,4-dihydroxy-5-isopropylbenzoyl group and in which position 5 of the isoidole moiety has been substituted by a (4-methylpiperazin-1-yl)methyl group. A second-generation Hsp90 inhibitor.	3.35	1	0	benzamides; isoindoles; N-alkylpiperazine; resorcinols; tertiary carboxamide	antineoplastic agent; Hsp90 inhibitor
mdv 3100 [no description available]	7.81	15	1	(trifluoromethyl)benzenes; benzamides; imidazolidinone; monofluorobenzenes; nitrile; thiocarbonyl compound	androgen antagonist; antineoplastic agent
cytochrome c-t Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.	2.11	1	0
apalutamide [no description available]	5.2	4	0
heme Heme: The color-furnishing portion of hemoglobin. It is found free in tissues and as the prosthetic group in many hemeproteins.. ferroheme : Any iron(II)--porphyrin coordination complex.. ferroheme b : Heme b in which the iron has oxidation state +2.. heme : A heme is any tetrapyrrolic chelate of iron.	2.21	1	0
cyclin d1 Cyclin D1: Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.	2.04	1	0
vt-464 VT-464: a CYP17A1 inhibitor with antineoplastic activity; structure in first source	4.14	2	0

Condition	Indicated	Relationship Strength	Studies	Trials
Cancer of Prostate [description not available]	0	7.87	29	0
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	0	7.87	29	0
Androgen-Independent Prostatic Cancer [description not available]	0	8.75	14	2
Prostatic Neoplasms, Castration-Resistant Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.	1	10.75	14	2
Metastase [description not available]	0	5.43	2	2
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	0	5.43	2	2
Breast Cancer [description not available]	0	2.61	2	0
Breast Neoplasms Tumors or cancer of the human BREAST.	0	2.61	2	0
Congenital Adrenal Hyperplasia [description not available]	0	3.04	1	0
Adrenal Hyperplasia, Congenital A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.	0	3.04	1	0
Invasiveness, Neoplasm [description not available]	0	3.04	1	0
Disease Exacerbation [description not available]	0	2.45	2	0
Hormone-Dependent Neoplasms [description not available]	0	3.38	2	0

3beta-hydroxy-17-(1h-benzimidazole-1-yl)androsta-5,16-diene

Description

Cross-References

Synonyms (55)

Research Excerpts

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (1)

Protein Targets (3)

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (65)

Molecular Functions (32)

Ceullar Components (12)

Bioassays (79)

Research

Studies (49)

Market Indicators

Research Demand Index: 11.51

Study Types

3beta-hydroxy-17-(1h-benzimidazole-1-yl)androsta-5,16-diene

Description

Cross-References

Synonyms (55)

Research Excerpts

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (1)

Protein Targets (3)

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (65)

Molecular Functions (32)

Ceullar Components (12)

Bioassays (79)

Research

Studies (49)

Market Indicators

Research Demand Index: 11.51

Study Types

Related Drugs (36)

Related Conditions (13)